Which has higher valuation & earnings, SABS or ACHV?

Achieve Life Sciences is trading at a lower price-to-earnings ratio than SAB Biotherapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio SAB Biotherapeutics N/A N/A $13.27M -$2.11 N/A Achieve Life Sciences N/A N/A -$54.65M -$1.12 N/A

Is SABS or ACHV more profitable?

SAB Biotherapeutics' return on equity of -0.29% beat Achieve Life Sciences' return on equity. Company Net Margins Return on Equity Return on Assets SAB Biotherapeutics N/A -0.29% -0.25% Achieve Life Sciences N/A -193.49% -111.88%

SAB Biotherapeutics (SABS) Competitors

$4.10 +0.77 (+22.97%)

As of 01:02 PM Eastern

Compare

SABS vs. LXRX, GERN, ACHV, RIGL, and IRWD

Should you buy SAB Biotherapeutics stock or one of its competitors? MarketBeat compares SAB Biotherapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with SAB Biotherapeutics include Lexicon Pharmaceuticals (LXRX), Geron (GERN), Achieve Life Sciences (ACHV), Rigel Pharmaceuticals (RIGL), and Ironwood Pharmaceuticals (IRWD). These companies are all part of the "biotechnology" industry.

How does SAB Biotherapeutics compare to Lexicon Pharmaceuticals?

Lexicon Pharmaceuticals (NASDAQ:LXRX) and SAB Biotherapeutics (NASDAQ:SABS) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, media sentiment, profitability, institutional ownership, earnings and valuation.

Lexicon Pharmaceuticals currently has a consensus price target of $4.55, indicating a potential upside of 131.55%. SAB Biotherapeutics has a consensus price target of $11.63, indicating a potential upside of 183.88%. Given SAB Biotherapeutics' stronger consensus rating and higher probable upside, analysts plainly believe SAB Biotherapeutics is more favorable than Lexicon Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lexicon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
SAB Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

SAB Biotherapeutics has lower revenue, but higher earnings than Lexicon Pharmaceuticals. Lexicon Pharmaceuticals is trading at a lower price-to-earnings ratio than SAB Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lexicon Pharmaceuticals	$69.64M	12.53	-$50.34M	-$0.07	N/A
SAB Biotherapeutics	N/A	N/A	$13.27M	-$2.11	N/A

In the previous week, Lexicon Pharmaceuticals and Lexicon Pharmaceuticals both had 3 articles in the media. SAB Biotherapeutics' average media sentiment score of 1.87 beat Lexicon Pharmaceuticals' score of 1.16 indicating that SAB Biotherapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Lexicon Pharmaceuticals	Positive
SAB Biotherapeutics	Very Positive

74.7% of Lexicon Pharmaceuticals shares are owned by institutional investors. Comparatively, 7.8% of SAB Biotherapeutics shares are owned by institutional investors. 14.0% of Lexicon Pharmaceuticals shares are owned by insiders. Comparatively, 25.1% of SAB Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Lexicon Pharmaceuticals has a beta of 1.07, meaning that its stock price is 7% more volatile than the broader market. Comparatively, SAB Biotherapeutics has a beta of 0.54, meaning that its stock price is 46% less volatile than the broader market.

SAB Biotherapeutics has a net margin of 0.00% compared to Lexicon Pharmaceuticals' net margin of -37.46%. SAB Biotherapeutics' return on equity of -0.29% beat Lexicon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lexicon Pharmaceuticals	-37.46%	-18.64%	-11.79%
SAB Biotherapeutics	N/A	-0.29%	-0.25%

Summary

SAB Biotherapeutics beats Lexicon Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

How does SAB Biotherapeutics compare to Geron?

Geron (NASDAQ:GERN) and SAB Biotherapeutics (NASDAQ:SABS) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, earnings, media sentiment, institutional ownership and profitability.

73.7% of Geron shares are held by institutional investors. Comparatively, 7.8% of SAB Biotherapeutics shares are held by institutional investors. 1.7% of Geron shares are held by company insiders. Comparatively, 25.1% of SAB Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Geron has a beta of 0.61, indicating that its share price is 39% less volatile than the broader market. Comparatively, SAB Biotherapeutics has a beta of 0.54, indicating that its share price is 46% less volatile than the broader market.

In the previous week, SAB Biotherapeutics had 2 more articles in the media than Geron. MarketBeat recorded 3 mentions for SAB Biotherapeutics and 1 mentions for Geron. SAB Biotherapeutics' average media sentiment score of 1.87 beat Geron's score of 0.93 indicating that SAB Biotherapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Geron	Positive
SAB Biotherapeutics	Very Positive

Geron currently has a consensus price target of $2.50, indicating a potential upside of 110.97%. SAB Biotherapeutics has a consensus price target of $11.63, indicating a potential upside of 183.88%. Given SAB Biotherapeutics' stronger consensus rating and higher possible upside, analysts plainly believe SAB Biotherapeutics is more favorable than Geron.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Geron	2 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00
SAB Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

SAB Biotherapeutics has a net margin of 0.00% compared to Geron's net margin of -35.48%. SAB Biotherapeutics' return on equity of -0.29% beat Geron's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Geron	-35.48%	-23.31%	-10.08%
SAB Biotherapeutics	N/A	-0.29%	-0.25%

SAB Biotherapeutics has lower revenue, but higher earnings than Geron. Geron is trading at a lower price-to-earnings ratio than SAB Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Geron	$183.88M	4.13	-$83.50M	-$0.11	N/A
SAB Biotherapeutics	N/A	N/A	$13.27M	-$2.11	N/A

Summary

SAB Biotherapeutics beats Geron on 11 of the 15 factors compared between the two stocks.

How does SAB Biotherapeutics compare to Achieve Life Sciences?

SAB Biotherapeutics (NASDAQ:SABS) and Achieve Life Sciences (NASDAQ:ACHV) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, risk, earnings, analyst recommendations, institutional ownership, valuation and media sentiment.

SAB Biotherapeutics presently has a consensus price target of $11.63, indicating a potential upside of 183.88%. Achieve Life Sciences has a consensus price target of $14.67, indicating a potential upside of 166.13%. Given SAB Biotherapeutics' higher probable upside, research analysts plainly believe SAB Biotherapeutics is more favorable than Achieve Life Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SAB Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
Achieve Life Sciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	3.00

SAB Biotherapeutics has a beta of 0.54, suggesting that its share price is 46% less volatile than the broader market. Comparatively, Achieve Life Sciences has a beta of 2.27, suggesting that its share price is 127% more volatile than the broader market.

In the previous week, SAB Biotherapeutics had 2 more articles in the media than Achieve Life Sciences. MarketBeat recorded 3 mentions for SAB Biotherapeutics and 1 mentions for Achieve Life Sciences. SAB Biotherapeutics' average media sentiment score of 1.87 equaled Achieve Life Sciences'average media sentiment score.

Company	Overall Sentiment
SAB Biotherapeutics	Very Positive
Achieve Life Sciences	Very Positive

Achieve Life Sciences is trading at a lower price-to-earnings ratio than SAB Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SAB Biotherapeutics	N/A	N/A	$13.27M	-$2.11	N/A
Achieve Life Sciences	N/A	N/A	-$54.65M	-$1.12	N/A

7.8% of SAB Biotherapeutics shares are held by institutional investors. Comparatively, 33.5% of Achieve Life Sciences shares are held by institutional investors. 25.1% of SAB Biotherapeutics shares are held by company insiders. Comparatively, 3.0% of Achieve Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

SAB Biotherapeutics' return on equity of -0.29% beat Achieve Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SAB Biotherapeutics	N/A	-0.29%	-0.25%
Achieve Life Sciences	N/A	-193.49%	-111.88%

Summary

SAB Biotherapeutics beats Achieve Life Sciences on 8 of the 13 factors compared between the two stocks.

How does SAB Biotherapeutics compare to Rigel Pharmaceuticals?

SAB Biotherapeutics (NASDAQ:SABS) and Rigel Pharmaceuticals (NASDAQ:RIGL) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, earnings, media sentiment, profitability, valuation and dividends.

In the previous week, SAB Biotherapeutics had 1 more articles in the media than Rigel Pharmaceuticals. MarketBeat recorded 3 mentions for SAB Biotherapeutics and 2 mentions for Rigel Pharmaceuticals. SAB Biotherapeutics' average media sentiment score of 1.87 beat Rigel Pharmaceuticals' score of 0.94 indicating that SAB Biotherapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
SAB Biotherapeutics	Very Positive
Rigel Pharmaceuticals	Positive

SAB Biotherapeutics currently has a consensus target price of $11.63, suggesting a potential upside of 183.88%. Rigel Pharmaceuticals has a consensus target price of $54.50, suggesting a potential upside of 62.61%. Given SAB Biotherapeutics' stronger consensus rating and higher possible upside, analysts clearly believe SAB Biotherapeutics is more favorable than Rigel Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SAB Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
Rigel Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

SAB Biotherapeutics has a beta of 0.54, suggesting that its share price is 46% less volatile than the broader market. Comparatively, Rigel Pharmaceuticals has a beta of 1.2, suggesting that its share price is 20% more volatile than the broader market.

Rigel Pharmaceuticals has a net margin of 121.50% compared to SAB Biotherapeutics' net margin of 0.00%. Rigel Pharmaceuticals' return on equity of 47.99% beat SAB Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SAB Biotherapeutics	N/A	-0.29%	-0.25%
Rigel Pharmaceuticals	121.50%	47.99%	32.40%

Rigel Pharmaceuticals has higher revenue and earnings than SAB Biotherapeutics. SAB Biotherapeutics is trading at a lower price-to-earnings ratio than Rigel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SAB Biotherapeutics	N/A	N/A	$13.27M	-$2.11	N/A
Rigel Pharmaceuticals	$294.28M	2.11	$367.02M	$18.72	1.79

7.8% of SAB Biotherapeutics shares are owned by institutional investors. Comparatively, 66.2% of Rigel Pharmaceuticals shares are owned by institutional investors. 25.1% of SAB Biotherapeutics shares are owned by company insiders. Comparatively, 10.5% of Rigel Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Rigel Pharmaceuticals beats SAB Biotherapeutics on 9 of the 15 factors compared between the two stocks.

How does SAB Biotherapeutics compare to Ironwood Pharmaceuticals?

SAB Biotherapeutics (NASDAQ:SABS) and Ironwood Pharmaceuticals (NASDAQ:IRWD) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, media sentiment, valuation, dividends, earnings and profitability.

SAB Biotherapeutics presently has a consensus price target of $11.63, suggesting a potential upside of 183.88%. Ironwood Pharmaceuticals has a consensus price target of $6.23, suggesting a potential upside of 69.15%. Given SAB Biotherapeutics' stronger consensus rating and higher possible upside, analysts clearly believe SAB Biotherapeutics is more favorable than Ironwood Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SAB Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
Ironwood Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.43

In the previous week, SAB Biotherapeutics had 1 more articles in the media than Ironwood Pharmaceuticals. MarketBeat recorded 3 mentions for SAB Biotherapeutics and 2 mentions for Ironwood Pharmaceuticals. SAB Biotherapeutics' average media sentiment score of 1.87 beat Ironwood Pharmaceuticals' score of 1.42 indicating that SAB Biotherapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
SAB Biotherapeutics	Very Positive
Ironwood Pharmaceuticals	Positive

7.8% of SAB Biotherapeutics shares are held by institutional investors. 25.1% of SAB Biotherapeutics shares are held by insiders. Comparatively, 9.3% of Ironwood Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

SAB Biotherapeutics has a beta of 0.54, meaning that its stock price is 46% less volatile than the broader market. Comparatively, Ironwood Pharmaceuticals has a beta of 0.25, meaning that its stock price is 75% less volatile than the broader market.

Ironwood Pharmaceuticals has higher revenue and earnings than SAB Biotherapeutics. SAB Biotherapeutics is trading at a lower price-to-earnings ratio than Ironwood Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SAB Biotherapeutics	N/A	N/A	$13.27M	-$2.11	N/A
Ironwood Pharmaceuticals	$296.15M	2.03	$24.02M	$0.60	6.14

Ironwood Pharmaceuticals has a net margin of 28.26% compared to SAB Biotherapeutics' net margin of 0.00%. SAB Biotherapeutics' return on equity of -0.29% beat Ironwood Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SAB Biotherapeutics	N/A	-0.29%	-0.25%
Ironwood Pharmaceuticals	28.26%	-39.65%	26.54%

Summary

SAB Biotherapeutics beats Ironwood Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

Get SAB Biotherapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SABS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SABS vs. The Competition

Export

Metric	SAB Biotherapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$313.50M	$3.40B	$6.50B	$12.36B
Dividend Yield	N/A	2.25%	2.67%	5.67%
P/E Ratio	-1.94	20.08	23.99	24.69
Price / Sales	N/A	322.83	538.03	166.93
Price / Cash	9.75	53.61	27.48	37.92
Price / Book	1.29	8.06	10.47	6.82
Net Income	$13.27M	$23.89M	$3.56B	$337.45M
7 Day Performance	20.44%	2.75%	1.21%	2.49%
1 Month Performance	10.68%	0.70%	2.14%	4.37%
1 Year Performance	139.47%	45.69%	26.24%	32.80%

SAB Biotherapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SABS SAB Biotherapeutics	4.1192 of 5 stars	$4.10 +23.0%	$11.63 +183.9%	+94.7%	$313.50M	N/A	N/A	140	Positive News Analyst Forecast Gap Up High Trading Volume
LXRX Lexicon Pharmaceuticals	1.8783 of 5 stars	$1.88 flat	$4.55 +142.0%	+185.9%	$835.09M	$49.80M	N/A	140
GERN Geron	2.0067 of 5 stars	$1.12 -0.9%	$2.50 +123.2%	-23.8%	$724.92M	$183.88M	N/A	70
ACHV Achieve Life Sciences	2.6949 of 5 stars	$5.60 +2.2%	$14.67 +161.9%	+69.8%	$562.57M	N/A	N/A	20	Gap Up
RIGL Rigel Pharmaceuticals	3.205 of 5 stars	$30.72 +2.1%	$54.50 +77.4%	+60.1%	$556.54M	$294.28M	1.64	160

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SABS) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

SAB Biotherapeutics (SABS) Competitors

SABS vs. LXRX, GERN, ACHV, RIGL, and IRWD

How does SAB Biotherapeutics compare to Lexicon Pharmaceuticals?

Summary

How does SAB Biotherapeutics compare to Geron?

Summary

How does SAB Biotherapeutics compare to Achieve Life Sciences?

Summary

How does SAB Biotherapeutics compare to Rigel Pharmaceuticals?

Summary

How does SAB Biotherapeutics compare to Ironwood Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SABS vs. The Competition

SAB Biotherapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

SAB Biotherapeutics (SABS) Competitors

SABS vs. LXRX, GERN, ACHV, RIGL, and IRWD

How does SAB Biotherapeutics compare to Lexicon Pharmaceuticals?

Do analysts rate LXRX or SABS?

Which has preferable earnings & valuation, LXRX or SABS?

Does the media prefer LXRX or SABS?

Do insiders and institutionals believe in LXRX or SABS?

Which has more volatility and risk, LXRX or SABS?

Is LXRX or SABS more profitable?

Summary

How does SAB Biotherapeutics compare to Geron?

Do insiders & institutionals hold more shares of GERN or SABS?

Which has more volatility and risk, GERN or SABS?

Does the media prefer GERN or SABS?

Do analysts prefer GERN or SABS?

Is GERN or SABS more profitable?

Which has preferable valuation and earnings, GERN or SABS?

Summary

How does SAB Biotherapeutics compare to Achieve Life Sciences?

Do analysts prefer SABS or ACHV?

Which has more risk & volatility, SABS or ACHV?

Does the media favor SABS or ACHV?

Which has higher valuation & earnings, SABS or ACHV?

Do institutionals and insiders believe in SABS or ACHV?

Is SABS or ACHV more profitable?

Summary

How does SAB Biotherapeutics compare to Rigel Pharmaceuticals?

Does the media favor SABS or RIGL?

Do analysts prefer SABS or RIGL?

Which has more volatility & risk, SABS or RIGL?

Is SABS or RIGL more profitable?

Which has preferable earnings & valuation, SABS or RIGL?

Do insiders and institutionals hold more shares of SABS or RIGL?

Summary

How does SAB Biotherapeutics compare to Ironwood Pharmaceuticals?

Do analysts recommend SABS or IRWD?

Does the media favor SABS or IRWD?

Do institutionals & insiders have more ownership in SABS or IRWD?

Which has more risk & volatility, SABS or IRWD?

Which has preferable earnings and valuation, SABS or IRWD?

Is SABS or IRWD more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SABS vs. The Competition

SAB Biotherapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools